CN113166815A - 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 - Google Patents
肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 Download PDFInfo
- Publication number
- CN113166815A CN113166815A CN201980076831.8A CN201980076831A CN113166815A CN 113166815 A CN113166815 A CN 113166815A CN 201980076831 A CN201980076831 A CN 201980076831A CN 113166815 A CN113166815 A CN 113166815A
- Authority
- CN
- China
- Prior art keywords
- marker
- lung cancer
- sample
- small cell
- cell lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710089372 Programmed cell death protein 1 Proteins 0.000 title claims abstract description 156
- 239000002981 blocking agent Substances 0.000 title claims abstract description 94
- 230000000694 effects Effects 0.000 title claims abstract description 57
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 47
- 102100023990 60S ribosomal protein L17 Human genes 0.000 title claims abstract 29
- 238000012216 screening Methods 0.000 title claims description 21
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 109
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 109
- 239000003550 marker Substances 0.000 claims abstract description 89
- 238000011282 treatment Methods 0.000 claims abstract description 70
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 241000194023 Streptococcus sanguinis Species 0.000 claims abstract description 19
- 241000588724 Escherichia coli Species 0.000 claims abstract description 16
- 241000588919 Citrobacter freundii Species 0.000 claims abstract description 13
- 241000962922 Clostridium sp. L2-50 Species 0.000 claims abstract description 11
- 241001183540 Pyramidobacter piscolens Species 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 107
- 230000004044 response Effects 0.000 claims description 91
- 238000012163 sequencing technique Methods 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 60
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 244000005700 microbiome Species 0.000 claims description 25
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 23
- 238000007637 random forest analysis Methods 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 239000013610 patient sample Substances 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 201000005202 lung cancer Diseases 0.000 claims description 15
- 208000020816 lung neoplasm Diseases 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 238000013179 statistical model Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 230000007102 metabolic function Effects 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 6
- 229950007712 camrelizumab Drugs 0.000 claims description 6
- 229960003301 nivolumab Drugs 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 108020004463 18S ribosomal RNA Proteins 0.000 claims description 5
- 238000004590 computer program Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000007671 third-generation sequencing Methods 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 127
- 241000894007 species Species 0.000 description 34
- 241000894006 Bacteria Species 0.000 description 18
- 230000000903 blocking effect Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000001747 exhibiting effect Effects 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 238000012549 training Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000000528 statistical test Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 238000012165 high-throughput sequencing Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 238000007400 DNA extraction Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 239000012270 PD-1 inhibitor Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- -1 /or Species 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000488157 Escherichia sp. Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000869037 Piscicola Species 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 241001183539 Pyramidobacter Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了肠道宏基因组在预测PD‑1抗体阻断剂对于癌症的治疗效果中的用途以及用于预测PD‑1抗体阻断剂对非小细胞肺癌患者治疗效果的标志物及应用。该标志物包括选自Streptococcussanguinis,Escherichia coli,Clostridium sp.L2‑50,Citrobacter freundii,Pyramidobacter piscolens,及其类似物中的至少一种。
Description
PCT国内申请,说明书已公开。
Claims (33)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/075825 WO2020168541A1 (zh) | 2019-02-22 | 2019-02-22 | 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113166815A true CN113166815A (zh) | 2021-07-23 |
CN113166815B CN113166815B (zh) | 2024-06-11 |
Family
ID=72144870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980076831.8A Active CN113166815B (zh) | 2019-02-22 | 2019-02-22 | 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113166815B (zh) |
WO (1) | WO2020168541A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105209919A (zh) * | 2013-03-15 | 2015-12-30 | 豪夫迈·罗氏有限公司 | 治疗pd-1和pd-l1相关疾患的生物标志物和方法 |
EP3012270A1 (en) * | 2014-10-23 | 2016-04-27 | Institut Gustave Roussy | Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
US20160303172A1 (en) * | 2013-11-21 | 2016-10-20 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment |
WO2017050855A1 (en) * | 2015-09-22 | 2017-03-30 | Institut Gustave Roussy | A scoring method for predicting the efficiency of a treatment with anti-pd-1 and/or anti-pd-l1 monoclonal antibodies |
CN107988373A (zh) * | 2018-01-10 | 2018-05-04 | 上海交通大学医学院附属仁济医院 | 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用 |
WO2018084204A1 (ja) * | 2016-11-02 | 2018-05-11 | 国立大学法人京都大学 | Pd-1シグナル阻害剤による疾患治療における有効性判定マーカー |
CN109266766A (zh) * | 2018-10-10 | 2019-01-25 | 中国人民解放军第三0二医院 | 肠道微生物作为胆管细胞癌诊断标志物的用途 |
-
2019
- 2019-02-22 WO PCT/CN2019/075825 patent/WO2020168541A1/zh active Application Filing
- 2019-02-22 CN CN201980076831.8A patent/CN113166815B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105209919A (zh) * | 2013-03-15 | 2015-12-30 | 豪夫迈·罗氏有限公司 | 治疗pd-1和pd-l1相关疾患的生物标志物和方法 |
US20160303172A1 (en) * | 2013-11-21 | 2016-10-20 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment |
EP3012270A1 (en) * | 2014-10-23 | 2016-04-27 | Institut Gustave Roussy | Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
WO2017050855A1 (en) * | 2015-09-22 | 2017-03-30 | Institut Gustave Roussy | A scoring method for predicting the efficiency of a treatment with anti-pd-1 and/or anti-pd-l1 monoclonal antibodies |
WO2018084204A1 (ja) * | 2016-11-02 | 2018-05-11 | 国立大学法人京都大学 | Pd-1シグナル阻害剤による疾患治療における有効性判定マーカー |
CN107988373A (zh) * | 2018-01-10 | 2018-05-04 | 上海交通大学医学院附属仁济医院 | 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用 |
CN109266766A (zh) * | 2018-10-10 | 2019-01-25 | 中国人民解放军第三0二医院 | 肠道微生物作为胆管细胞癌诊断标志物的用途 |
Non-Patent Citations (2)
Title |
---|
KEISHI ADACHI等: "Microbial biomarkers for immune checkpoint blockade therapy against cancer", 《JOURNAL OF GASTROENTEROL》, no. 53, pages 999 - 1005 * |
YUKI OWADA-OZAKI等: "A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors", 《JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY》, vol. 45, no. 9, pages 1234 - 1237 * |
Also Published As
Publication number | Publication date |
---|---|
CN113166815B (zh) | 2024-06-11 |
WO2020168541A1 (zh) | 2020-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105368944B (zh) | 可检测疾病的生物标志物及其用途 | |
WO2021184412A1 (zh) | 基于肠道微生物的双相情感障碍生物标志物及其筛选应用 | |
CN105296590B (zh) | 大肠癌标志物及其应用 | |
CN111440884A (zh) | 源于肠道的诊断肌少症的菌群及其用途 | |
CN105132518B (zh) | 大肠癌标志物及其应用 | |
CN104540962A (zh) | 糖尿病生物标志物及其应用 | |
EP3629904A1 (en) | Methods and systems for identifying or monitoring lung disease | |
Kandimalla et al. | EpiPanGI Dx: a cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers | |
WO2020244018A1 (zh) | 一种精神分裂症的小规模生物标志物组合、其应用及metaphlan2筛选方法 | |
CN110904213B (zh) | 一种基于肠道菌群的溃疡性结肠炎生物标志物及其应用 | |
WO2016050111A1 (en) | Biomarkers for rheumatoid arthritis and usage thereof | |
WO2019205188A1 (zh) | 抑郁症生物标志物及其用途 | |
CN111455074B (zh) | 用于评估胰腺癌化疗疗效的微生物菌群标志物及其应用 | |
EP4247980A2 (en) | Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment | |
WO2016112488A1 (en) | Biomarkers for colorectal cancer related diseases | |
CN111020020A (zh) | 一种精神分裂症的生物标志物组合、其应用及metaphlan2筛选方法 | |
CN110396538B (zh) | 偏头痛生物标志物及其用途 | |
CN112384634B (zh) | 骨质疏松生物标志物及其用途 | |
CN113166815B (zh) | 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 | |
US20240153588A1 (en) | Systems and methods for identifying microbial biosynthetic genetic clusters | |
CN112481380B (zh) | 一种评估晚期膀胱癌抗肿瘤免疫治疗反应性和预后生存的标志物及其应用 | |
CN112011605B (zh) | 微生物菌群在疾病诊断中的应用 | |
CN112063709A (zh) | 一种以微生物作为诊断标志物的重症肌无力的诊断试剂盒及应用 | |
CN111020021A (zh) | 一种基于肠道菌群的小规模精神分裂症生物标志物组合、其应用及mOTU筛选方法 | |
JP2011004743A (ja) | 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40048536 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |